Julie R. Brahmer, MD, MSc, is the Co-Director of the Division of Upper Aerodigestive Malignancies, Professor of Oncology, and Marilyn Meyerhoff Professor in Thoracic Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. In addition to serving as Co-Leader of the Cancer Immunology Program, she also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus. She is co-principal investigator of the Johns Hopkins' National Clinical Trials Network and helps direct all oncology cooperative group activities on the Johns Hopkins campuses. Dr. Brahmer is an international leader in lung cancer clinical trials research with particular expertise in drug development for thoracic malignancies and immunotherapy. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center, College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, she later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer's research interests include leading early phase immunotherapy trials including the anti-PD-1 antibodies as well as international phase III studies of immunotherapies in lung cancer and mesothelioma. She led the first in human trial of MDX-1106 now known as nivolumab. Her research has been recognized by her peers in IASLC. At the 2024 World Conference on Lung Cancer, she was awarded the Paul Bunn Lifetime Scientific Achievement Award for her contributions to lung cancer research. She is a member of the Johns Hopkins Kimmel Cancer Center immunotherapy related toxicity management team and co-leads NCCN and SITC immunotherapy toxicity guideline development for these national and international organizations. Dr. Brahmer has been a member of SITC since 2013 and served on various committees as well as the Board of Directors from 2022-2024. Dr. Brahmer also is a member of scientific advisory boards of lung cancer patient advocacy groups: LUNGevity, Lung Cancer Research Foundation, and Lung Cancer Foundation of America.